Abbott Laboratories (Pakistan) Limited (PSX:ABOT)
Pakistan
· Delayed Price · Currency is PKR 919.98
+0.44 (0.05%)
At close: Apr 28, 2026
PSX:ABOT Income Statement
Financials in millions PKR. Fiscal year is January - December.
Millions PKR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 75,756 | 75,398 | 68,177 | 55,475 | 49,258 | 42,570 | Upgrade
|
| Revenue Growth (YoY) | 9.01% | 10.59% | 22.90% | 12.62% | 15.71% | 20.65% | Upgrade
|
| Cost of Revenue | 48,222 | 48,720 | 48,283 | 43,715 | 34,821 | 26,554 | Upgrade
|
| Gross Profit | 27,534 | 26,678 | 19,894 | 11,760 | 14,436 | 16,015 | Upgrade
|
| Selling, General & Admin | 12,561 | 12,287 | 10,362 | 8,989 | 7,835 | 7,232 | Upgrade
|
| Other Operating Expenses | 1,442 | 1,444 | 862.48 | 303.19 | 590.58 | 777.55 | Upgrade
|
| Operating Expenses | 14,003 | 13,731 | 11,225 | 9,292 | 8,425 | 8,009 | Upgrade
|
| Operating Income | 13,531 | 12,947 | 8,669 | 2,468 | 6,011 | 8,006 | Upgrade
|
| Interest Expense | -80.66 | -66.46 | -11.74 | -22.18 | -25.41 | -54.48 | Upgrade
|
| Interest & Investment Income | 688.29 | 688.29 | 621.67 | 893.59 | 995.1 | 571.13 | Upgrade
|
| Currency Exchange Gain (Loss) | -182.3 | -182.3 | -16.2 | -1,341 | -779.79 | -240.34 | Upgrade
|
| Other Non Operating Income (Expenses) | 39.48 | 70.12 | 58.55 | 71.27 | 41.08 | 108.9 | Upgrade
|
| EBT Excluding Unusual Items | 13,996 | 13,457 | 9,321 | 2,069 | 6,242 | 8,392 | Upgrade
|
| Gain (Loss) on Sale of Assets | 113.38 | 113.38 | 31.14 | 20.26 | -94.33 | 18.92 | Upgrade
|
| Asset Writedown | -349.57 | -349.57 | -225.04 | - | - | - | Upgrade
|
| Other Unusual Items | 278.89 | 278.89 | - | 500.05 | - | - | Upgrade
|
| Pretax Income | 14,038 | 13,500 | 9,128 | 2,590 | 6,148 | 8,410 | Upgrade
|
| Income Tax Expense | 5,731 | 5,533 | 3,893 | 2,328 | 3,143 | 2,443 | Upgrade
|
| Net Income | 8,307 | 7,967 | 5,234 | 261.78 | 3,004 | 5,967 | Upgrade
|
| Net Income to Common | 8,307 | 7,967 | 5,234 | 261.78 | 3,004 | 5,967 | Upgrade
|
| Net Income Growth | 56.29% | 52.20% | 1899.50% | -91.29% | -49.65% | 31.57% | Upgrade
|
| Shares Outstanding (Basic) | 98 | 98 | 98 | 98 | 98 | 98 | Upgrade
|
| Shares Outstanding (Diluted) | 98 | 98 | 98 | 98 | 98 | 98 | Upgrade
|
| EPS (Basic) | 84.85 | 81.37 | 53.46 | 2.67 | 30.69 | 60.95 | Upgrade
|
| EPS (Diluted) | 84.85 | 81.37 | 53.46 | 2.67 | 30.69 | 60.95 | Upgrade
|
| EPS Growth | 56.28% | 52.20% | 1899.50% | -91.29% | -49.65% | 31.57% | Upgrade
|
| Free Cash Flow | 6,249 | 7,441 | 1,652 | -3,137 | 212.23 | 5,768 | Upgrade
|
| Free Cash Flow Per Share | 63.83 | 76.01 | 16.87 | -32.04 | 2.17 | 58.92 | Upgrade
|
| Dividend Per Share | 40.000 | 40.000 | 10.000 | - | 15.000 | 40.000 | Upgrade
|
| Dividend Growth | 300.00% | 300.00% | - | - | -62.50% | - | Upgrade
|
| Gross Margin | 36.35% | 35.38% | 29.18% | 21.20% | 29.31% | 37.62% | Upgrade
|
| Operating Margin | 17.86% | 17.17% | 12.72% | 4.45% | 12.20% | 18.81% | Upgrade
|
| Profit Margin | 10.97% | 10.57% | 7.68% | 0.47% | 6.10% | 14.02% | Upgrade
|
| Free Cash Flow Margin | 8.25% | 9.87% | 2.42% | -5.65% | 0.43% | 13.55% | Upgrade
|
| EBITDA | 15,306 | 14,709 | 10,366 | 3,966 | 7,368 | 9,119 | Upgrade
|
| EBITDA Margin | 20.21% | 19.51% | 15.20% | 7.15% | 14.96% | 21.42% | Upgrade
|
| D&A For EBITDA | 1,776 | 1,762 | 1,697 | 1,498 | 1,357 | 1,113 | Upgrade
|
| EBIT | 13,531 | 12,947 | 8,669 | 2,468 | 6,011 | 8,006 | Upgrade
|
| EBIT Margin | 17.86% | 17.17% | 12.72% | 4.45% | 12.20% | 18.81% | Upgrade
|
| Effective Tax Rate | 40.83% | 40.99% | 42.65% | 89.89% | 51.13% | 29.05% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.